|
TUBGCP3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.46319999450029E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.34259999965359E-07 |
| Normal-vs-Stage2 |
4.213500E-04 |
| Normal-vs-Stage3 |
7.45289996384457E-09 |
| Normal-vs-Stage4 |
2.50820000324836E-08 |
| Stage1-vs-Stage2 |
8.030600E-01 |
| Stage1-vs-Stage3 |
1.221230E-01 |
| Stage1-vs-Stage4 |
1.382610E-01 |
| Stage2-vs-Stage3 |
2.021200E-01 |
| Stage2-vs-Stage4 |
1.668610E-01 |
| Stage3-vs-Stage4 |
7.664400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.05280000273211E-08 |
| Normal-vs-AfricanAmerican |
1.975810E-03 |
| Normal-vs-Asian |
1.640810E-03 |
| Caucasian-vs-AfricanAmerican |
4.598400E-01 |
| Caucasian-vs-Asian |
1.500020E-01 |
| AfricanAmerican-vs-Asian |
7.618600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.52830004207516E-09 |
| Normal-vs-Female |
2.21079999973561E-07 |
| Male-vs-Female |
1.414640E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.07329999946104E-07 |
| Normal-vs-Age(41-60Yrs) |
9.80119999605122E-08 |
| Normal-vs-Age(61-80Yrs) |
6.40620001490788E-09 |
| Normal-vs-Age(81-100Yrs) |
7.187500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.614000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.138600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.541800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.095600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.420000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.400600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.971800E-01 |
| Classical-VS-Follicular |
5.215000E-01 |
| Classical-VS-Other |
2.424200E-01 |
| Classical-VS-Normal |
1.72160000033728E-07 |
| Tall-VS-Follicular |
6.428400E-01 |
| Tall-VS-Other |
5.100800E-01 |
| Tall-VS-Normal |
1.76399999999299E-05 |
| Follicular-VS-Other |
5.023600E-01 |
| Follicular-VS-Normal |
1.85652999999952E-05 |
| Other-VS-Normal |
2.321600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.18610000043873E-07 |
| Normal-vs-N1 |
1.37260000032668E-07 |
| N0-vs-N1 |
5.175600E-01 |
|
|
